2026 International Spring Forum
April 15, 2026 | 12:00 PM EST
Upcoming Webinar
Vorasidenib: the First and Only mIDH1/2 Inhibitor for Patients With Grade 2 mIDH Glioma
Date: December 5, 2024 | 12:00 AM
Explore how vorasidenib, the first mIDH1/2 inhibitor for grade 2 gliomas with IDH1/2 mutations, is transforming treatment.
Dr. Tresa McGranahan, MD, PhD from Scripps Clinic Medical Group will cover:
- The impact of IDH1 and IDH2 mutations
- The role of molecular profiling in treatment decisions
- Vorasidenib’s mechanism of action, clinical efficacy, and safety for patients with grade 2 astrocytoma or oligodendroglioma